Ibrutinib is a first-in-class, oral, covalent inhibitor of BTK that has produced notable responses in combination with dexamethasone in heavily pre-treated MM patients in a Phase II trial [149] (Table 3). Here, BTK is linked to Miyoshi myopathy.